• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Elisabeth M. Paietta, PhD, Defines Minimum Residual Disease (MRD) and Discusses the Current Challenges of MRD Implementation

Article

Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.

Elisabeth M. Paietta, PhD, Professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, defines minimum residual disease (MRD) and discusses its clinical significance. She then describes the methodological and therapeutic challenges that face clinical MRD implementation.

This video was taken on Sunday, December 9, at the American Society of Hematology's 54th Annual Meeting in Atlanta, GA.

Related Videos
Khush Kharidia, MD
Kimberly Westrich, MA, chief strategy officer, National Pharmaceutical Council
Harry Travis, BS Pharm, MBA, president at The Travis Group, LLC
 Brigid Groves, PharmD, MS, vice president, professional affairs, American Pharmacists Association
Chelsea Renfro, PharmD, research and engagement pharmacist, Vanderbilt Specialty Pharmacy
Chicago skyline with words "CHEST 2025 Recap Chicago, Illinois" | Image credit: SeanPavonePhoto - stock.adobe.com
Screenshot of an interview with Kristina Crothers, MD
James Simon, MD – Image credit: AJMC
Brooke Aggarwal, EdD – screenshot by AJMC
JoAnn Pinkerton, MD
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.